Parotid glands have a dysregulated immune response following radiation therapy.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Parotid Gland*/radiation effects ; Head and Neck Neoplasms*; Mice ; Animals ; Insulin-Like Growth Factor I ; Salivary Glands ; Immunity

Head and neck cancer treatment often consists of surgical resection of the tumor followed by ionizing radiation (IR), which can damage surrounding tissues and cause adverse side effects. The underlying mechanisms of radiation-induced salivary gland dysfunction are not fully understood, and treatment options are scarce and ineffective. The wound healing process is a necessary response to tissue injury, and broadly consists of inflammatory, proliferative, and redifferentiation phases with immune cells playing key roles in all three phases. In this study, select immune cells were phenotyped and quantified, and certain cytokine and chemokine concentrations were measured in mouse parotid glands after IR. Further, we used a model where glandular function is restored to assess the immune phenotype in a regenerative response. These data suggest that irradiated parotid tissue does not progress through a typical inflammatory response observed in wounds that heal. Specifically, total immune cells (CD45+) decrease at days 2 and 5 following IR, macrophages (F4/80+CD11b+) decrease at day 2 and 5 and increase at day 30, while neutrophils (Ly6G+CD11b+) significantly increase at day 30 following IR. Additionally, radiation treatment reduces CD3- cells at all time points, significantly increases CD3+/CD4+CD8+ double positive cells, and significantly reduces CD3+/CD4-CD8- double negative cells at day 30 after IR. Previous data indicate that post-IR treatment with IGF-1 restores salivary gland function at day 30, and IGF-1 injections attenuate the increase in macrophages, neutrophils, and CD4+CD8+ T cells observed at day 30 following IR. Taken together, these data indicate that parotid salivary tissue exhibits a dysregulated immune response following radiation treatment which may contribute to chronic loss of function phenotype in head and neck cancer survivors.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Gunning et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Radiother Oncol. 1994 Jul;32(1):29-36. (PMID: 7938676)
Front Oncol. 2012 Sep 19;2:119. (PMID: 23050243)
Expert Rev Mol Med. 2011 Jul 11;13:e23. (PMID: 21740602)
Radiat Res. 2012 Dec;178(6):505-23. (PMID: 23106210)
Am J Pathol. 2013 Nov;183(5):1352-1363. (PMID: 24091222)
Cancer Lett. 2015 Nov 28;368(2):164-72. (PMID: 25841996)
J Leukoc Biol. 2003 Jun;73(6):713-21. (PMID: 12773503)
World J Gastroenterol. 2007 Jun 14;13(22):3047-55. (PMID: 17589919)
iScience. 2023 Apr 11;26(5):106660. (PMID: 37168562)
Sci Rep. 2020 Jul 29;10(1):12716. (PMID: 32728041)
Cancer Res. 2020 Dec 15;80(24):5531-5542. (PMID: 32998998)
Nat Rev Immunol. 2010 Jun;10(6):427-39. (PMID: 20498669)
J Exp Med. 2018 Feb 5;215(2):423-440. (PMID: 29339450)
J Dent Res. 2009 Oct;88(10):894-903. (PMID: 19783796)
Adv Wound Care (New Rochelle). 2015 Nov 1;4(11):631-640. (PMID: 26543677)
PLoS One. 2014 Nov 19;9(11):e112840. (PMID: 25409170)
Front Physiol. 2018 May 01;9:419. (PMID: 29765329)
Ther Adv Med Oncol. 2020 May 26;12:1758835920926822. (PMID: 32518598)
Front Genet. 2022 Aug 17;13:928328. (PMID: 36061172)
Adv Wound Care (New Rochelle). 2022 Mar;11(3):121-131. (PMID: 34238032)
Cancer Res. 2016 Mar 1;76(5):1170-80. (PMID: 26759233)
Front Bioeng Biotechnol. 2021 Jul 21;9:697671. (PMID: 34381764)
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):523-9. (PMID: 19147016)
PLoS One. 2010 Jan 05;5(1):e8437. (PMID: 20052413)
Int J Radiat Biol. 2006 Sep;82(9):686-97. (PMID: 17032631)
J Exp Med. 1999 Oct 4;190(7):923-34. (PMID: 10510082)
Eur Respir J. 2018 Mar 1;51(3):. (PMID: 29496785)
Cell Tissue Res. 2018 Mar;371(3):531-539. (PMID: 29383445)
PLoS One. 2012;7(12):e51363. (PMID: 23236487)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
J Clin Invest. 2019 Jun 17;129(7):2629-2639. (PMID: 31205028)
Biomed J. 2017 Aug;40(4):200-211. (PMID: 28918908)
Circulation. 2012 Jul 24;126(4):418-29. (PMID: 22705886)
Biochem Biophys Res Commun. 1999 Nov;265(1):194-9. (PMID: 10548513)
Int J Dent. 2020 Mar 26;2020:8176260. (PMID: 32377200)
Clin Cancer Res. 2008 Mar 15;14(6):1868-76. (PMID: 18347190)
Int J Cancer. 2011 Jun 15;128(12):2923-32. (PMID: 20824715)
PLoS One. 2013;8(2):e57052. (PMID: 23451141)
Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8727-32. (PMID: 15173593)
Int Rev Cell Mol Biol. 2019;342:73-93. (PMID: 30635094)
Cell Mol Life Sci. 2016 Oct;73(20):3861-85. (PMID: 27180275)
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5324-9. (PMID: 12695566)
J Immunol. 2016 Mar 1;196(5):2010-4. (PMID: 26826250)
Int J Radiat Biol. 2003 Mar;79(3):159-67. (PMID: 12745880)
J Clin Med. 2020 Dec 18;9(12):. (PMID: 33353023)
PLoS One. 2014 Dec 01;9(12):e113183. (PMID: 25437438)
PLoS One. 2009;4(3):e4663. (PMID: 19252741)
Eur J Cancer. 2017 Oct;84:304-314. (PMID: 28863385)
BMC Cancer. 2010 Aug 10;10:417. (PMID: 20698985)
Int J Mol Sci. 2021 Dec 16;22(24):. (PMID: 34948290)
Am J Pathol. 2009 Dec;175(6):2454-62. (PMID: 19850888)
Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G556-65. (PMID: 12909564)
Am J Pathol. 2007 Mar;170(3):818-29. (PMID: 17322368)
Clin Dermatol. 2007 Jan-Feb;25(1):19-25. (PMID: 17276197)
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):579-86. (PMID: 20638195)
J Invest Dermatol. 2007 Mar;127(3):514-25. (PMID: 17299434)
Adv Wound Care (New Rochelle). 2020 Apr 1;9(4):184-198. (PMID: 32117582)
Apoptosis. 2018 Oct;23(9-10):470-483. (PMID: 29995207)
FASEB J. 2000 Dec;14(15):2525-31. (PMID: 11099471)
Cancer Invest. 1999;17(1):56-72. (PMID: 10999050)
Adv Wound Care (New Rochelle). 2013 Sep;2(7):379-388. (PMID: 24527354)
Postepy Dermatol Alergol. 2014 May;31(2):84-91. (PMID: 25097473)
Annu Rev Immunol. 2003;21:107-37. (PMID: 12414720)
BMC Res Notes. 2014 Mar 07;7:128. (PMID: 24602333)
Biomed Res Int. 2013;2013:123241. (PMID: 23586015)
J Dent Res. 2023 May;102(5):546-554. (PMID: 36726289)
J Natl Cancer Inst. 2017 Aug 1;109(8):. (PMID: 28376190)
Nature. 1997 Nov 27;390(6658):350-1. (PMID: 9389474)
Sci Rep. 2018 Apr 20;8(1):6347. (PMID: 29679075)
J Dent Res. 2013 Oct;92(10):911-7. (PMID: 23884556)
J Trauma. 2010 Oct;69(4):843-8. (PMID: 20173656)
Sci Immunol. 2020 May 1;5(47):. (PMID: 32358172)
Int J Mol Sci. 2018 Oct 18;19(10):. (PMID: 30340330)
J Invest Dermatol. 2008 Jul;128(7):1812-20. (PMID: 18185533)
Front Oncol. 2012 Dec 17;2:191. (PMID: 23251903)
Cancer Res. 2001 Dec 15;61(24):8859-65. (PMID: 11751409)
Nat Commun. 2016 Dec 23;7:13898. (PMID: 28008921)
Adv Wound Care (New Rochelle). 2019 Nov 1;8(11):527-537. (PMID: 31637099)
Cureus. 2019 Feb 26;11(2):e4142. (PMID: 31058025)

R01 DE029166 United States DE NIDCR NIH HHS

67763-96-6 (Insulin-Like Growth Factor I)

Date Created: 20240312 Date Completed: 20240314 Latest Revision: 20240316

20240316

PMC10931461

10.1371/journal.pone.0297387

38470874